ID   NTRK2_HUMAN             Reviewed;         822 AA.
AC   Q16620; B1ANZ4; B4DFV9; Q16675; Q59GJ1; Q8WXJ5; Q8WXJ6; Q8WXJ7;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-OCT-2022, entry version 233.
DE   RecName: Full=BDNF/NT-3 growth factors receptor;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:15494731};
DE   AltName: Full=GP145-TrkB;
DE            Short=Trk-B;
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 2;
DE   AltName: Full=TrkB tyrosine kinase;
DE   AltName: Full=Tropomyosin-related kinase B;
DE   Flags: Precursor;
GN   Name=NTRK2; Synonyms=TRKB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB).
RC   TISSUE=Hippocampus;
RX   PubMed=7789988; DOI=10.1016/0888-7543(95)80055-q;
RA   Nakagawara A., Liu X.-G., Ikegaki N., White P.S., Yamashiro D.J.,
RA   Nycum L.M., Biegel J.A., Brodeur G.M.;
RT   "Cloning and chromosomal localization of the human TRK-B tyrosine kinase
RT   receptor gene (NTRK2).";
RL   Genomics 25:538-546(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB AND TRKB-T1).
RC   TISSUE=Brain;
RX   PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995;
RA   Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P.,
RA   Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.;
RT   "Human trks: molecular cloning, tissue distribution, and expression of
RT   extracellular domain immunoadhesins.";
RL   J. Neurosci. 15:477-491(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RC   TISSUE=Hippocampus;
RX   PubMed=7936202; DOI=10.1016/0306-4522(94)90507-x;
RA   Allen S.J., Dawbarn D., Eckford S.D., Wilcock G.K., Ashcroft M.,
RA   Colebrook S.M., Feeney R., Macgowan S.H.;
RT   "Cloning of a non-catalytic form of human trkB and distribution of
RT   messenger RNA for trkB in human brain.";
RL   Neuroscience 60:825-834(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB; TRKB-T1; TRKB-T-SHC; 4 AND 5),
RP   ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=11798182; DOI=10.1006/bbrc.2001.6301;
RA   Stoilov P., Castren E., Stamm S.;
RT   "Analysis of the human TrkB gene genomic organization reveals novel TrkB
RT   isoforms, unusual gene length, and splicing mechanism.";
RL   Biochem. Biophys. Res. Commun. 290:1054-1065(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), AND VARIANT ARG-309.
RA   Steinbeck J.A., Thomsen S., Wessig J., Leypoldt F., Lewerenz J.,
RA   Methner A.;
RT   "Full length truncated TrkB sequence identified in a screen for genes
RT   regulated by ischemic preconditioning.";
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-N-T1).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T-TK).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   FUNCTION, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-67; ASN-95; ASN-121;
RP   ASN-178; ASN-205; ASN-241; ASN-254; ASN-280; ASN-338 AND ASN-412.
RX   PubMed=7574684; DOI=10.1006/abbi.1995.1460;
RA   Haniu M., Talvenheimo J., Le J., Katta V., Welcher A., Rohde M.F.;
RT   "Extracellular domain of neurotrophin receptor trkB: disulfide structure,
RT   N-glycosylation sites, and ligand binding.";
RL   Arch. Biochem. Biophys. 322:256-264(1995).
RN   [12]
RP   INTERACTION WITH FRS2.
RX   PubMed=10092678; DOI=10.1074/jbc.274.14.9861;
RA   Meakin S.O., MacDonald J.I.S., Gryz E.A., Kubu C.J., Verdi J.M.;
RT   "The signaling adapter FRS-2 competes with Shc for binding to the nerve
RT   growth factor receptor TrkA. A model for discriminating proliferation and
RT   differentiation.";
RL   J. Biol. Chem. 274:9861-9870(1999).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-67; ASN-121 AND ASN-254.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [14]
RP   ALTERNATIVE SPLICING (ISOFORMS TRKB-T-TK AND TRKB-N-T1).
RX   PubMed=20193039; DOI=10.1111/j.1471-4159.2010.06662.x;
RA   Luberg K., Wong J., Weickert C.S., Timmusk T.;
RT   "Human TrkB gene: novel alternative transcripts, protein isoforms and
RT   expression pattern in the prefrontal cerebral cortex during postnatal
RT   development.";
RL   J. Neurochem. 113:952-964(2010).
RN   [15] {ECO:0007744|PDB:1WWB}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 283-385, AND DISULFIDE BONDS.
RX   PubMed=10388563; DOI=10.1006/jmbi.1999.2816;
RA   Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D.,
RA   Bass S.H., de Vos A.M.;
RT   "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and
RT   TrkC.";
RL   J. Mol. Biol. 290:149-159(1999).
RN   [16] {ECO:0007744|PDB:1HCF}
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 284-383 IN COMPLEX WITH NTF4, AND
RP   DISULFIDE BONDS.
RX   PubMed=11738045; DOI=10.1016/s0969-2126(01)00681-5;
RA   Banfield M.J., Naylor R.L., Robertson A.G., Allen S.J., Dawbarn D.,
RA   Brady R.L.;
RT   "Specificity in Trk receptor:neurotrophin interactions: the crystal
RT   structure of TrkB-d5 in complex with neurotrophin-4/5.";
RL   Structure 9:1191-1199(2001).
RN   [17]
RP   VARIANT OBHD CYS-706, CHARACTERIZATION OF VARIANT OBHD CYS-706, FUNCTION AS
RP   A BDNF-ACTIVATED RECEPTOR, CATALYTIC ACTIVITY, PHOSPHORYLATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15494731; DOI=10.1038/nn1336;
RA   Yeo G.S., Connie Hung C.C., Rochford J., Keogh J., Gray J.,
RA   Sivaramakrishnan S., O'Rahilly S., Farooqi I.S.;
RT   "A de novo mutation affecting human TrkB associated with severe obesity and
RT   developmental delay.";
RL   Nat. Neurosci. 7:1187-1189(2004).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] PHE-138.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [19]
RP   VARIANTS ILE-697; GLY-699 AND CYS-718.
RX   PubMed=18293376; DOI=10.1002/humu.20707;
RA   Marchetti A., Felicioni L., Pelosi G., Del Grammastro M., Fumagalli C.,
RA   Sciarrotta M., Malatesta S., Chella A., Barassi F., Mucilli F.,
RA   Camplese P., D'Antuono T., Sacco R., Buttitta F.;
RT   "Frequent mutations in the neurotrophic tyrosine receptor kinase gene
RT   family in large cell neuroendocrine carcinoma of the lung.";
RL   Hum. Mutat. 29:609-616(2008).
RN   [20]
RP   VARIANT OBHD 444-GLY--GLY-822 DEL.
RX   PubMed=27884935; DOI=10.1136/jmedgenet-2016-104215;
RA   Miller K.A., Twigg S.R., McGowan S.J., Phipps J.M., Fenwick A.L.,
RA   Johnson D., Wall S.A., Noons P., Rees K.E., Tidey E.A., Craft J.,
RA   Taylor J., Taylor J.C., Goos J.A., Swagemakers S.M., Mathijssen I.M.,
RA   van der Spek P.J., Lord H., Lester T., Abid N., Cilliers D., Hurst J.A.,
RA   Morton J.E., Sweeney E., Weber A., Wilson L.C., Wilkie A.O.;
RT   "Diagnostic value of exome and whole genome sequencing in
RT   craniosynostosis.";
RL   J. Med. Genet. 54:260-268(2017).
RN   [21]
RP   INVOLVEMENT IN DEE58, VARIANT DEE58 CYS-434, AND VARIANT OBHD ILE-704.
RX   PubMed=29100083; DOI=10.1016/j.ajhg.2017.09.008;
RG   Deciphering Developmental Disorders Study;
RA   Hamdan F.F., Myers C.T., Cossette P., Lemay P., Spiegelman D.,
RA   Laporte A.D., Nassif C., Diallo O., Monlong J., Cadieux-Dion M.,
RA   Dobrzeniecka S., Meloche C., Retterer K., Cho M.T., Rosenfeld J.A., Bi W.,
RA   Massicotte C., Miguet M., Brunga L., Regan B.M., Mo K., Tam C.,
RA   Schneider A., Hollingsworth G., FitzPatrick D.R., Donaldson A., Canham N.,
RA   Blair E., Kerr B., Fry A.E., Thomas R.H., Shelagh J., Hurst J.A.,
RA   Brittain H., Blyth M., Lebel R.R., Gerkes E.H., Davis-Keppen L., Stein Q.,
RA   Chung W.K., Dorison S.J., Benke P.J., Fassi E., Corsten-Janssen N.,
RA   Kamsteeg E.J., Mau-Them F.T., Bruel A.L., Verloes A., Ounap K.,
RA   Wojcik M.H., Albert D.V.F., Venkateswaran S., Ware T., Jones D., Liu Y.C.,
RA   Mohammad S.S., Bizargity P., Bacino C.A., Leuzzi V., Martinelli S.,
RA   Dallapiccola B., Tartaglia M., Blumkin L., Wierenga K.J., Purcarin G.,
RA   O'Byrne J.J., Stockler S., Lehman A., Keren B., Nougues M.C., Mignot C.,
RA   Auvin S., Nava C., Hiatt S.M., Bebin M., Shao Y., Scaglia F., Lalani S.R.,
RA   Frye R.E., Jarjour I.T., Jacques S., Boucher R.M., Riou E., Srour M.,
RA   Carmant L., Lortie A., Major P., Diadori P., Dubeau F., D'Anjou G.,
RA   Bourque G., Berkovic S.F., Sadleir L.G., Campeau P.M., Kibar Z.,
RA   Lafreniere R.G., Girard S.L., Mercimek-Mahmutoglu S., Boelman C.,
RA   Rouleau G.A., Scheffer I.E., Mefford H.C., Andrade D.M., Rossignol E.,
RA   Minassian B.A., Michaud J.L.;
RT   "High rate of recurrent de novo mutations in developmental and epileptic
RT   encephalopathies.";
RL   Am. J. Hum. Genet. 101:664-685(2017).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in the development and the
CC       maturation of the central and the peripheral nervous systems through
CC       regulation of neuron survival, proliferation, migration,
CC       differentiation, and synapse formation and plasticity (By similarity).
CC       Receptor for BDNF/brain-derived neurotrophic factor and
CC       NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3
CC       which is less efficient in activating the receptor but regulates neuron
CC       survival through NTRK2 (PubMed:7574684, PubMed:15494731). Upon ligand-
CC       binding, undergoes homodimerization, autophosphorylation and activation
CC       (PubMed:15494731). Recruits, phosphorylates and/or activates several
CC       downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that
CC       regulate distinct overlapping signaling cascades. Through SHC1, FRS2,
CC       SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for
CC       instance neuronal differentiation including neurite outgrowth. Through
CC       the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade
CC       that mainly regulates growth and survival. Through PLCG1 and the
CC       downstream protein kinase C-regulated pathways controls synaptic
CC       plasticity. Thereby, plays a role in learning and memory by regulating
CC       both short term synaptic function and long-term potentiation. PLCG1
CC       also leads to NF-Kappa-B activation and the transcription of genes
CC       involved in cell survival. Hence, it is able to suppress anoikis, the
CC       apoptosis resulting from loss of cell-matrix interactions. May also
CC       play a role in neutrophin-dependent calcium signaling in glial cells
CC       and mediate communication between neurons and glia.
CC       {ECO:0000250|UniProtKB:P15209, ECO:0000269|PubMed:15494731,
CC       ECO:0000269|PubMed:7574684}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:15494731};
CC   -!- ACTIVITY REGULATION: The neuronal activity and the influx of calcium
CC       positively regulate the kinase activity and the internalization of the
CC       receptor which are both important for active signaling. Regulated by
CC       NGFR that may control the internalization of the receptor. NGFR may
CC       also stimulate the activation by BDNF compared to NTF3 and NTF4. SH2D1A
CC       inhibits the autophosphorylation of the receptor, and alters the
CC       recruitment and activation of downstream effectors and signaling
CC       cascades. The formation of active receptors dimers able to fully
CC       transduce the ligand-mediated signal, may be negatively regulated by
CC       the formation of inactive heterodimers with the non-catalytic isoforms
CC       (By similarity). {ECO:0000250|UniProtKB:P15209,
CC       ECO:0000250|UniProtKB:Q63604}.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures. Interacts
CC       (phosphorylated upon activation by BDNF) with SHC1; mediates SHC1
CC       phosphorylation and activation. Interacts (phosphorylated upon
CC       activation by BDNF) with PLCG1 and/or PLCG2; mediates PLCG1
CC       phosphorylation and activation. Interacts with SH2B1 and SH2B2.
CC       Interacts with NGFR; may regulate the ligand specificity of the
CC       receptor (By similarity). Interacts with SORCS2; this interaction is
CC       important for normal targeting to post-synaptic densities in response
CC       to high-frequency stimulation (By similarity). Interacts
CC       (phosphorylated upon ligand-binding) with SH2D1A; regulates NTRK2.
CC       Interacts with SQSTM1 and KIDINS220 (By similarity). Interacts
CC       (phosphorylated upon ligand-binding) with FRS2; activates the MAPK
CC       signaling pathway (PubMed:10092678). Interacts with APPL1 (By
CC       similarity). Interacts with MAPK8IP3/JIP3 and KLC1; interaction with
CC       KLC1 is mediated by MAPK8IP3/JIP3 (By similarity). Interacts with
CC       SORL1; this interaction facilitates NTRK2 trafficking between synaptic
CC       plasma membranes, postsynaptic densities and cell soma, hence
CC       positively regulates BDNF signaling (By similarity).
CC       {ECO:0000250|UniProtKB:P04629, ECO:0000250|UniProtKB:P15209,
CC       ECO:0000250|UniProtKB:Q63604, ECO:0000269|PubMed:10092678,
CC       ECO:0000269|PubMed:11738045}.
CC   -!- INTERACTION:
CC       Q16620; Q16288: NTRK3; NbExp=3; IntAct=EBI-3904881, EBI-3936704;
CC       Q16620; Q03114: Cdk5; Xeno; NbExp=3; IntAct=EBI-3904881, EBI-2008531;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15494731};
CC       Single-pass type I membrane protein {ECO:0000305}. Endosome membrane
CC       {ECO:0000250|UniProtKB:P15209}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P15209}. Early endosome membrane
CC       {ECO:0000250|UniProtKB:P15209}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q63604}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:Q63604}. Cytoplasm, perinuclear region
CC       {ECO:0000250|UniProtKB:Q63604}. Postsynaptic density
CC       {ECO:0000250|UniProtKB:P15209}. Note=Internalized to endosomes upon
CC       ligand-binding. {ECO:0000250|UniProtKB:P15209}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=TrkB; Synonyms=gp145-TrkB;
CC         IsoId=Q16620-1; Sequence=Displayed;
CC       Name=TrkB-T1;
CC         IsoId=Q16620-2; Sequence=VSP_002901, VSP_002902;
CC       Name=TrkB-T-Shc;
CC         IsoId=Q16620-3; Sequence=VSP_002903, VSP_002904;
CC       Name=4;
CC         IsoId=Q16620-4; Sequence=VSP_041942;
CC       Name=5;
CC         IsoId=Q16620-5; Sequence=VSP_041942, VSP_002903, VSP_002904;
CC       Name=TrkB-T-TK;
CC         IsoId=Q16620-6; Sequence=VSP_042178, VSP_042179;
CC       Name=TrkB-N-T1;
CC         IsoId=Q16620-7; Sequence=VSP_042177, VSP_002901, VSP_002902;
CC   -!- TISSUE SPECIFICITY: Isoform TrkB is expressed in the central and
CC       peripheral nervous system. In the central nervous system (CNS),
CC       expression is observed in the cerebral cortex, hippocampus, thalamus,
CC       choroid plexus, granular layer of the cerebellum, brain stem, and
CC       spinal cord. In the peripheral nervous system, it is expressed in many
CC       cranial ganglia, the ophthalmic nerve, the vestibular system, multiple
CC       facial structures, the submaxillary glands, and dorsal root ganglia.
CC       Isoform TrkB-T1 is mainly expressed in the brain but also detected in
CC       other tissues including pancreas, kidney and heart. Isoform TrkB-T-Shc
CC       is predominantly expressed in the brain. {ECO:0000269|PubMed:11798182,
CC       ECO:0000269|PubMed:7936202}.
CC   -!- DEVELOPMENTAL STAGE: Widely expressed in fetal brain.
CC       {ECO:0000269|PubMed:7936202}.
CC   -!- PTM: Phosphorylated. Undergoes ligand-mediated autophosphorylation that
CC       is required for interaction with SHC1 and PLCG1 and other downstream
CC       effectors. Isoform TrkB-T-Shc is not phosphorylated.
CC       {ECO:0000269|PubMed:15494731}.
CC   -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation;
CC       regulated by NGFR. Ubiquitination regulates the internalization of the
CC       receptor (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Developmental and epileptic encephalopathy 58 (DEE58)
CC       [MIM:617830]: A form of epileptic encephalopathy, a heterogeneous group
CC       of severe early-onset epilepsies characterized by refractory seizures,
CC       neurodevelopmental impairment, and poor prognosis. Development is
CC       normal prior to seizure onset, after which cognitive and motor delays
CC       become apparent. DEE58 is an autosomal dominant condition characterized
CC       by onset of refractory seizures in the first days or months of life.
CC       {ECO:0000269|PubMed:29100083}. Note=The disease may be caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Obesity, hyperphagia, and developmental delay (OBHD)
CC       [MIM:613886]: A disorder characterized by early-onset obesity,
CC       hyperphagia, and severe developmental delay in motor function, speech,
CC       and language. {ECO:0000269|PubMed:15494731,
CC       ECO:0000269|PubMed:27884935, ECO:0000269|PubMed:29100083}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase since the
CC       first Trk was isolated as an oncogenic protein which was the result of
CC       a fusion between the tropomyosin gene TPM3 and NTRK1.
CC   -!- MISCELLANEOUS: [Isoform TrkB-T1]: Non-catalytic isoform. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NTRK2ID41589ch9q21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U12140; AAC51371.1; -; mRNA.
DR   EMBL; S76473; AAB33109.1; -; mRNA.
DR   EMBL; S76474; AAB33110.1; -; mRNA.
DR   EMBL; X75958; CAA53571.1; -; mRNA.
DR   EMBL; AF410899; AAL67965.1; -; mRNA.
DR   EMBL; AF410900; AAL67966.1; -; mRNA.
DR   EMBL; AF410901; AAL67967.1; -; mRNA.
DR   EMBL; AF508964; AAM77876.1; -; mRNA.
DR   EMBL; AB209118; BAD92355.1; -; mRNA.
DR   EMBL; AK294285; BAG57570.1; -; mRNA.
DR   EMBL; AL390777; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445532; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL596132; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471089; EAW62688.1; -; Genomic_DNA.
DR   EMBL; BC031835; AAH31835.1; -; mRNA.
DR   CCDS; CCDS35050.1; -. [Q16620-1]
DR   CCDS; CCDS35051.1; -. [Q16620-5]
DR   CCDS; CCDS35052.1; -. [Q16620-3]
DR   CCDS; CCDS35053.1; -. [Q16620-2]
DR   CCDS; CCDS6671.1; -. [Q16620-4]
DR   PIR; A56853; A56853.
DR   PIR; I73631; I73631.
DR   RefSeq; NP_001007098.1; NM_001007097.2. [Q16620-2]
DR   RefSeq; NP_001018074.1; NM_001018064.2. [Q16620-1]
DR   RefSeq; NP_001018075.1; NM_001018065.2. [Q16620-5]
DR   RefSeq; NP_001018076.1; NM_001018066.2. [Q16620-3]
DR   RefSeq; NP_006171.2; NM_006180.4. [Q16620-4]
DR   RefSeq; XP_005252058.1; XM_005252001.2. [Q16620-4]
DR   RefSeq; XP_005252060.1; XM_005252003.2. [Q16620-4]
DR   RefSeq; XP_005252061.1; XM_005252004.2. [Q16620-4]
DR   RefSeq; XP_005252063.1; XM_005252006.3. [Q16620-5]
DR   RefSeq; XP_005252064.1; XM_005252007.3.
DR   RefSeq; XP_011517020.1; XM_011518718.2. [Q16620-1]
DR   RefSeq; XP_011517022.1; XM_011518720.2. [Q16620-3]
DR   RefSeq; XP_016870240.1; XM_017014751.1. [Q16620-4]
DR   RefSeq; XP_016870241.1; XM_017014752.1. [Q16620-1]
DR   RefSeq; XP_016870242.1; XM_017014753.1. [Q16620-1]
DR   RefSeq; XP_016870243.1; XM_017014754.1.
DR   RefSeq; XP_016870244.1; XM_017014755.1. [Q16620-5]
DR   RefSeq; XP_016870245.1; XM_017014756.1.
DR   RefSeq; XP_016870246.1; XM_017014757.1.
DR   RefSeq; XP_016870247.1; XM_017014758.1.
DR   RefSeq; XP_016870248.1; XM_017014759.1.
DR   RefSeq; XP_016870249.1; XM_017014760.1. [Q16620-2]
DR   RefSeq; XP_016870250.1; XM_017014761.1.
DR   PDB; 1HCF; X-ray; 2.70 A; X/Y=286-383.
DR   PDB; 1WWB; X-ray; 2.10 A; X=283-385.
DR   PDB; 2MFQ; NMR; -; B=497-519.
DR   PDB; 4ASZ; X-ray; 1.70 A; A=527-822.
DR   PDB; 4AT3; X-ray; 1.77 A; A=527-822.
DR   PDB; 4AT4; X-ray; 2.36 A; A=527-822.
DR   PDB; 4AT5; X-ray; 1.71 A; A=527-822.
DR   PDB; 5MO9; X-ray; 2.59 A; X=278-426.
DR   PDBsum; 1HCF; -.
DR   PDBsum; 1WWB; -.
DR   PDBsum; 2MFQ; -.
DR   PDBsum; 4ASZ; -.
DR   PDBsum; 4AT3; -.
DR   PDBsum; 4AT4; -.
DR   PDBsum; 4AT5; -.
DR   PDBsum; 5MO9; -.
DR   AlphaFoldDB; Q16620; -.
DR   SMR; Q16620; -.
DR   BioGRID; 110970; 37.
DR   DIP; DIP-5720N; -.
DR   IntAct; Q16620; 105.
DR   STRING; 9606.ENSP00000277120; -.
DR   BindingDB; Q16620; -.
DR   ChEMBL; CHEMBL4898; -.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB11986; Entrectinib.
DR   DrugBank; DB11823; Esketamine.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB14723; Larotrectinib.
DR   DrugCentral; Q16620; -.
DR   GuidetoPHARMACOLOGY; 1818; -.
DR   TCDB; 8.A.23.1.38; the basigin (basigin) family.
DR   GlyConnect; 1029; 12 N-Linked glycans (7 sites).
DR   GlyGen; Q16620; 13 sites, 1 Asn glycan (1 site), 12 N-linked glycans (7 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; Q16620; -.
DR   PhosphoSitePlus; Q16620; -.
DR   BioMuta; NTRK2; -.
DR   DMDM; 2497560; -.
DR   EPD; Q16620; -.
DR   jPOST; Q16620; -.
DR   MassIVE; Q16620; -.
DR   PaxDb; Q16620; -.
DR   PeptideAtlas; Q16620; -.
DR   PRIDE; Q16620; -.
DR   ProteomicsDB; 60955; -. [Q16620-1]
DR   ProteomicsDB; 60956; -. [Q16620-2]
DR   ProteomicsDB; 60957; -. [Q16620-3]
DR   ProteomicsDB; 60958; -. [Q16620-4]
DR   ProteomicsDB; 60959; -. [Q16620-5]
DR   ProteomicsDB; 60960; -. [Q16620-6]
DR   ProteomicsDB; 60961; -. [Q16620-7]
DR   ABCD; Q16620; 146 sequenced antibodies.
DR   Antibodypedia; 2081; 1457 antibodies from 47 providers.
DR   DNASU; 4915; -.
DR   Ensembl; ENST00000277120.8; ENSP00000277120.3; ENSG00000148053.18. [Q16620-4]
DR   Ensembl; ENST00000304053.11; ENSP00000306167.7; ENSG00000148053.18. [Q16620-3]
DR   Ensembl; ENST00000359847.4; ENSP00000352906.3; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000376208.6; ENSP00000365381.1; ENSG00000148053.18. [Q16620-3]
DR   Ensembl; ENST00000376213.6; ENSP00000365386.1; ENSG00000148053.18. [Q16620-1]
DR   Ensembl; ENST00000395882.6; ENSP00000379221.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000685720.1; ENSP00000509031.1; ENSG00000148053.18. [Q16620-5]
DR   Ensembl; ENST00000686259.1; ENSP00000509743.1; ENSG00000148053.18. [Q16620-1]
DR   Ensembl; ENST00000686322.1; ENSP00000510032.1; ENSG00000148053.18. [Q16620-7]
DR   Ensembl; ENST00000686324.1; ENSP00000510134.1; ENSG00000148053.18. [Q16620-4]
DR   Ensembl; ENST00000686443.1; ENSP00000509093.1; ENSG00000148053.18. [Q16620-3]
DR   Ensembl; ENST00000686496.1; ENSP00000510060.1; ENSG00000148053.18. [Q16620-1]
DR   Ensembl; ENST00000687148.1; ENSP00000510717.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000687596.1; ENSP00000509999.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000687636.1; ENSP00000508829.1; ENSG00000148053.18. [Q16620-5]
DR   Ensembl; ENST00000688013.1; ENSP00000508443.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000689685.1; ENSP00000509169.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000689815.1; ENSP00000510451.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000690281.1; ENSP00000510757.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000691415.1; ENSP00000509058.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000691788.1; ENSP00000509401.1; ENSG00000148053.18. [Q16620-1]
DR   Ensembl; ENST00000692181.1; ENSP00000510619.1; ENSG00000148053.18. [Q16620-1]
DR   Ensembl; ENST00000692389.1; ENSP00000508497.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000692506.1; ENSP00000508622.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000692762.1; ENSP00000510071.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000693109.1; ENSP00000509456.1; ENSG00000148053.18. [Q16620-2]
DR   Ensembl; ENST00000693539.1; ENSP00000510640.1; ENSG00000148053.18. [Q16620-5]
DR   GeneID; 4915; -.
DR   KEGG; hsa:4915; -.
DR   MANE-Select; ENST00000277120.8; ENSP00000277120.3; NM_006180.6; NP_006171.2. [Q16620-4]
DR   UCSC; uc004anz.1; human. [Q16620-1]
DR   CTD; 4915; -.
DR   DisGeNET; 4915; -.
DR   GeneCards; NTRK2; -.
DR   HGNC; HGNC:8032; NTRK2.
DR   HPA; ENSG00000148053; Tissue enhanced (brain, thyroid gland).
DR   MalaCards; NTRK2; -.
DR   MIM; 600456; gene.
DR   MIM; 613886; phenotype.
DR   MIM; 617830; phenotype.
DR   neXtProt; NX_Q16620; -.
DR   OpenTargets; ENSG00000148053; -.
DR   Orphanet; 3451; Infantile spasms syndrome.
DR   Orphanet; 442835; Non-specific early-onset epileptic encephalopathy.
DR   Orphanet; 251615; Pilomyxoid astrocytoma.
DR   PharmGKB; PA31818; -.
DR   VEuPathDB; HostDB:ENSG00000148053; -.
DR   eggNOG; KOG1026; Eukaryota.
DR   GeneTree; ENSGT00940000155181; -.
DR   HOGENOM; CLU_000288_74_1_1; -.
DR   InParanoid; Q16620; -.
DR   OMA; TCSCEIM; -.
DR   PhylomeDB; Q16620; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; Q16620; -.
DR   Reactome; R-HSA-187024; NGF-independant TRKA activation.
DR   Reactome; R-HSA-9024909; BDNF activates NTRK2 (TRKB) signaling.
DR   Reactome; R-HSA-9025046; NTF3 activates NTRK2 (TRKB) signaling.
DR   Reactome; R-HSA-9026357; NTF4 activates NTRK2 (TRKB) signaling.
DR   Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS.
DR   Reactome; R-HSA-9026527; Activated NTRK2 signals through PLCG1.
DR   Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K.
DR   Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3.
DR   Reactome; R-HSA-9032500; Activated NTRK2 signals through FYN.
DR   Reactome; R-HSA-9032759; NTRK2 activates RAC1.
DR   Reactome; R-HSA-9032845; Activated NTRK2 signals through CDK5.
DR   SignaLink; Q16620; -.
DR   SIGNOR; Q16620; -.
DR   BioGRID-ORCS; 4915; 10 hits in 1102 CRISPR screens.
DR   ChiTaRS; NTRK2; human.
DR   EvolutionaryTrace; Q16620; -.
DR   GeneWiki; TrkB_receptor; -.
DR   GenomeRNAi; 4915; -.
DR   Pharos; Q16620; Tclin.
DR   PRO; PR:Q16620; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q16620; protein.
DR   Bgee; ENSG00000148053; Expressed in cranial nerve II and 194 other tissues.
DR   ExpressionAtlas; Q16620; baseline and differential.
DR   Genevisible; Q16620; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0043679; C:axon terminus; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; IBA:GO_Central.
DR   GO; GO:0005769; C:early endosome; ISS:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0014069; C:postsynaptic density; ISS:ARUK-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0043195; C:terminal bouton; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0048403; F:brain-derived neurotrophic factor binding; ISS:UniProtKB.
DR   GO; GO:0060175; F:brain-derived neurotrophic factor receptor activity; IMP:UniProtKB.
DR   GO; GO:0043121; F:neurotrophin binding; IDA:UniProtKB.
DR   GO; GO:0005030; F:neurotrophin receptor activity; IBA:GO_Central.
DR   GO; GO:0002020; F:protease binding; IPI:ARUK-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0031547; P:brain-derived neurotrophic factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; IBA:GO_Central.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IBA:GO_Central.
DR   GO; GO:0021954; P:central nervous system neuron development; ISS:UniProtKB.
DR   GO; GO:0021987; P:cerebral cortex development; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0007631; P:feeding behavior; IEA:Ensembl.
DR   GO; GO:0014047; P:glutamate secretion; IEA:Ensembl.
DR   GO; GO:0007612; P:learning; ISS:UniProtKB.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl.
DR   GO; GO:0022011; P:myelination in peripheral nervous system; IEA:Ensembl.
DR   GO; GO:1902430; P:negative regulation of amyloid-beta formation; IGI:ARUK-UCL.
DR   GO; GO:2000811; P:negative regulation of anoikis; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; ISS:UniProtKB.
DR   GO; GO:0019227; P:neuronal action potential propagation; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0048935; P:peripheral nervous system neuron development; IEA:Ensembl.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB.
DR   GO; GO:0051896; P:regulation of protein kinase B signaling; IBA:GO_Central.
DR   GO; GO:0046548; P:retinal rod cell development; IEA:Ensembl.
DR   GO; GO:0099183; P:trans-synaptic signaling by BDNF, modulating synaptic transmission; IEA:Ensembl.
DR   GO; GO:0099551; P:trans-synaptic signaling by neuropeptide, modulating synaptic transmission; IBA:GO_Central.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   IDEAL; IID00672; -.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR000372; LRRNT.
DR   InterPro; IPR020777; NTRK.
DR   InterPro; IPR020455; NTRK2.
DR   InterPro; IPR031635; NTRK_LRRCT.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF16920; LRRCT_2; 1.
DR   Pfam; PF01462; LRRNT; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01941; NTKRECEPTOR2.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00013; LRRNT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Cell projection; Cytoplasm; Developmental protein; Differentiation;
KW   Disease variant; Disulfide bond; Endosome; Epilepsy; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis;
KW   Nucleotide-binding; Obesity; Phosphoprotein; Receptor; Reference proteome;
KW   Repeat; Signal; Synapse; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..31
FT   CHAIN           32..822
FT                   /note="BDNF/NT-3 growth factors receptor"
FT                   /id="PRO_0000016727"
FT   TOPO_DOM        32..430
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        431..454
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        455..822
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          32..61
FT                   /note="LRRNT"
FT   REPEAT          92..113
FT                   /note="LRR 1"
FT   REPEAT          116..137
FT                   /note="LRR 2"
FT   DOMAIN          148..196
FT                   /note="LRRCT"
FT   DOMAIN          197..282
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          295..365
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          538..807
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          455..466
FT                   /note="Interaction with MAPK8IP3/JIP3"
FT                   /evidence="ECO:0000250|UniProtKB:Q63604"
FT   REGION          475..498
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        475..496
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        676
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         544..552
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         572
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            516
FT                   /note="Interaction with SHC1"
FT                   /evidence="ECO:0000250"
FT   SITE            706
FT                   /note="Interaction with SH2D1A"
FT                   /evidence="ECO:0000250"
FT   SITE            817
FT                   /note="Interaction with PLCG1"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         516
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P15209"
FT   MOD_RES         702
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q63604"
FT   MOD_RES         706
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q63604"
FT   MOD_RES         707
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q63604"
FT   MOD_RES         817
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q63604"
FT   CARBOHYD        67
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:7574684"
FT   CARBOHYD        95
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7574684"
FT   CARBOHYD        121
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:7574684"
FT   CARBOHYD        178
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7574684"
FT   CARBOHYD        205
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7574684"
FT   CARBOHYD        241
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7574684"
FT   CARBOHYD        254
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:7574684"
FT   CARBOHYD        280
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7574684"
FT   CARBOHYD        325
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        338
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7574684"
FT   CARBOHYD        412
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7574684"
FT   DISULFID        32..38
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:7574684"
FT   DISULFID        36..45
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:7574684"
FT   DISULFID        152..176
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:7574684"
FT   DISULFID        154..194
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:7574684"
FT   DISULFID        218..266
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:7574684"
FT   DISULFID        302..345
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:10388563, ECO:0000269|PubMed:11738045,
FT                   ECO:0000269|PubMed:7574684, ECO:0007744|PDB:1HCF,
FT                   ECO:0007744|PDB:1WWB, ECO:0007744|PDB:5MO9"
FT   VAR_SEQ         1..156
FT                   /note="Missing (in isoform TrkB-N-T1)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042177"
FT   VAR_SEQ         465
FT                   /note="K -> KDFSWFGFGKVKSRQGV (in isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:11798182"
FT                   /id="VSP_041942"
FT   VAR_SEQ         467..477
FT                   /note="PASVISNDDDS -> FVLFHKIPLDG (in isoform TrkB-T1 and
FT                   isoform TrkB-N-T1)"
FT                   /evidence="ECO:0000303|PubMed:11798182,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202,
FT                   ECO:0000303|Ref.5"
FT                   /id="VSP_002901"
FT   VAR_SEQ         478..822
FT                   /note="Missing (in isoform TrkB-T1 and isoform TrkB-N-T1)"
FT                   /evidence="ECO:0000303|PubMed:11798182,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202,
FT                   ECO:0000303|Ref.5"
FT                   /id="VSP_002902"
FT   VAR_SEQ         529..537
FT                   /note="FVQHIKRHN -> WPRGSPKTA (in isoform TrkB-T-Shc and
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:11798182"
FT                   /id="VSP_002903"
FT   VAR_SEQ         538..822
FT                   /note="Missing (in isoform TrkB-T-Shc and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:11798182"
FT                   /id="VSP_002904"
FT   VAR_SEQ         710..735
FT                   /note="GGHTMLPIRWMPPESIMYRKFTTESD -> SSCADQRPQGPLSLRDPCCICL
FT                   LRLS (in isoform TrkB-T-TK)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_042178"
FT   VAR_SEQ         736..822
FT                   /note="Missing (in isoform TrkB-T-TK)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_042179"
FT   VARIANT         138
FT                   /note="L -> F (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041470"
FT   VARIANT         309
FT                   /note="G -> R"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_016320"
FT   VARIANT         338
FT                   /note="N -> Y (in dbSNP:rs1047856)"
FT                   /id="VAR_011973"
FT   VARIANT         434
FT                   /note="Y -> C (in DEE58; unknown pathological significance;
FT                   dbSNP:rs886041091)"
FT                   /evidence="ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080659"
FT   VARIANT         444..822
FT                   /note="Missing (in OBHD)"
FT                   /evidence="ECO:0000269|PubMed:27884935"
FT                   /id="VAR_080660"
FT   VARIANT         545
FT                   /note="G -> V (in dbSNP:rs1075108)"
FT                   /id="VAR_049715"
FT   VARIANT         697
FT                   /note="M -> I (in a lung carcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:18293376"
FT                   /id="VAR_046518"
FT   VARIANT         699
FT                   /note="R -> G (in a lung carcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:18293376"
FT                   /id="VAR_046519"
FT   VARIANT         704
FT                   /note="T -> I (in OBHD; unknown pathological significance;
FT                   dbSNP:rs1554774973)"
FT                   /evidence="ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080661"
FT   VARIANT         706
FT                   /note="Y -> C (in OBHD; expressed normally on the cell
FT                   surface; results in markedly impaired ligand-induced
FT                   phosphorylation as well as impaired downstream MAPK1
FT                   phosphorylation; dbSNP:rs121434633)"
FT                   /evidence="ECO:0000269|PubMed:15494731"
FT                   /id="VAR_065890"
FT   VARIANT         718
FT                   /note="R -> C (in a lung carcinoma sample; somatic
FT                   mutation; dbSNP:rs1324578301)"
FT                   /evidence="ECO:0000269|PubMed:18293376"
FT                   /id="VAR_046520"
FT   STRAND          285..292
FT                   /evidence="ECO:0007829|PDB:5MO9"
FT   STRAND          300..308
FT                   /evidence="ECO:0007829|PDB:1WWB"
FT   STRAND          314..319
FT                   /evidence="ECO:0007829|PDB:1WWB"
FT   STRAND          322..324
FT                   /evidence="ECO:0007829|PDB:1WWB"
FT   STRAND          328..337
FT                   /evidence="ECO:0007829|PDB:1WWB"
FT   STRAND          339..350
FT                   /evidence="ECO:0007829|PDB:1WWB"
FT   HELIX           353..355
FT                   /evidence="ECO:0007829|PDB:1WWB"
FT   STRAND          357..364
FT                   /evidence="ECO:0007829|PDB:1WWB"
FT   STRAND          369..376
FT                   /evidence="ECO:0007829|PDB:1WWB"
FT   STRAND          380..382
FT                   /evidence="ECO:0007829|PDB:5MO9"
FT   STRAND          500..503
FT                   /evidence="ECO:0007829|PDB:2MFQ"
FT   STRAND          506..512
FT                   /evidence="ECO:0007829|PDB:2MFQ"
FT   TURN            515..517
FT                   /evidence="ECO:0007829|PDB:2MFQ"
FT   HELIX           535..537
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   STRAND          538..545
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   STRAND          552..557
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   STRAND          567..574
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           579..592
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   STRAND          603..607
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   STRAND          609..618
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           625..631
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           634..638
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   STRAND          641..643
FT                   /evidence="ECO:0007829|PDB:4AT5"
FT   HELIX           650..669
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           679..681
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   STRAND          682..684
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           686..688
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   STRAND          690..692
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           698..701
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           703..705
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   STRAND          707..709
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   TURN            710..712
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   STRAND          713..715
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           717..719
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           722..727
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           732..747
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   TURN            748..750
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   TURN            753..756
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           759..768
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           780..789
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           794..796
FT                   /evidence="ECO:0007829|PDB:4ASZ"
FT   HELIX           800..813
FT                   /evidence="ECO:0007829|PDB:4ASZ"
SQ   SEQUENCE   822 AA;  91999 MW;  2FEB9159948F0D13 CRC64;
     MSSWIRWHGP AMARLWGFCW LVVGFWRAAF ACPTSCKCSA SRIWCSDPSP GIVAFPRLEP
     NSVDPENITE IFIANQKRLE IINEDDVEAY VGLRNLTIVD SGLKFVAHKA FLKNSNLQHI
     NFTRNKLTSL SRKHFRHLDL SELILVGNPF TCSCDIMWIK TLQEAKSSPD TQDLYCLNES
     SKNIPLANLQ IPNCGLPSAN LAAPNLTVEE GKSITLSCSV AGDPVPNMYW DVGNLVSKHM
     NETSHTQGSL RITNISSDDS GKQISCVAEN LVGEDQDSVN LTVHFAPTIT FLESPTSDHH
     WCIPFTVKGN PKPALQWFYN GAILNESKYI CTKIHVTNHT EYHGCLQLDN PTHMNNGDYT
     LIAKNEYGKD EKQISAHFMG WPGIDDGANP NYPDVIYEDY GTAANDIGDT TNRSNEIPST
     DVTDKTGREH LSVYAVVVIA SVVGFCLLVM LFLLKLARHS KFGMKGPASV ISNDDDSASP
     LHHISNGSNT PSSSEGGPDA VIIGMTKIPV IENPQYFGIT NSQLKPDTFV QHIKRHNIVL
     KRELGEGAFG KVFLAECYNL CPEQDKILVA VKTLKDASDN ARKDFHREAE LLTNLQHEHI
     VKFYGVCVEG DPLIMVFEYM KHGDLNKFLR AHGPDAVLMA EGNPPTELTQ SQMLHIAQQI
     AAGMVYLASQ HFVHRDLATR NCLVGENLLV KIGDFGMSRD VYSTDYYRVG GHTMLPIRWM
     PPESIMYRKF TTESDVWSLG VVLWEIFTYG KQPWYQLSNN EVIECITQGR VLQRPRTCPQ
     EVYELMLGCW QREPHMRKNI KGIHTLLQNL AKASPVYLDI LG
//
